Stoke Therapeutics (NASDAQ:STOK) Given “Buy” Rating at HC Wainwright

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 201.72% from the stock’s current price.

Several other brokerages also recently commented on STOK. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. Wedbush lifted their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. JPMorgan Chase & Co. increased their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday, March 26th. Finally, TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.57.

Stoke Therapeutics Stock Down 2.8 %

Shares of STOK opened at $11.60 on Tuesday. The stock has a market cap of $604.59 million, a P/E ratio of -4.89 and a beta of 0.82. The business’s fifty day moving average is $10.23 and its 200 day moving average is $6.68. Stoke Therapeutics has a 12-month low of $3.35 and a 12-month high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to analyst estimates of $3.70 million. On average, analysts expect that Stoke Therapeutics will post -2.28 EPS for the current year.

Insider Buying and Selling

In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at $126,550.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Skorpios Trust sold 3,600,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,622,741 shares of company stock valued at $41,935,115. 11.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its stake in Stoke Therapeutics by 2.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 107,254 shares of the company’s stock worth $423,000 after purchasing an additional 2,926 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after acquiring an additional 6,636 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics during the first quarter valued at approximately $141,000. Dorsey & Whitney Trust CO LLC bought a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $43,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Stoke Therapeutics in the 3rd quarter worth approximately $48,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.